{"trade_id": "quiver_2026-06-08_T000278_PFE", "bioguide_id": "T000278", "member_name": "Tommy Tuberville", "party": "R", "chamber": "Senate", "ticker": "PFE", "company_name": "Pfizer Inc.", "sector": "Health Care", "industry": "Pharmaceuticals", "asset_description_raw": "PFE", "transaction_type": "sale_full", "amount_range": "15001.0", "amount_lower": 15001, "transaction_date": "2026-06-08", "disclosure_date": "2026-07-16", "disclosure_lag_days": 38, "in_jurisdiction": true, "committees_with_jurisdiction": ["Senate Committee on Health, Education, Labor, and Pensions", "Senate Committee on Veterans' Affairs", "Senate Special Committee on Aging"], "enrichment": {"ollama_resolved": false, "resolution_method": "quiverquant_direct"}, "ingested_at": "2026-07-17T01:00:05.501160+00:00", "narrative": "The trade involving Tommy Tuberville\u2019s sale of Pfizer shares on June 8, 2026, was flagged due to a high correlation score of 81.57, driven by event timing (0 days apart), committee overlap in the healthcare sector, and a pre-event trade. These factors suggest a potential alignment between the trade and recent lobbying activities targeting CMS, DOC, and FAA by entities in the healthcare sector, though no direct causation is implied. The disclosure lag of 38 days further warrants scrutiny to assess timing relative to relevant regulatory or policy developments."}